Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind dose-ranging study of GRT0151Y versus oxycodone controlled release and placebo in chronic knee osteoarthritis pain
2005-003360-26Phase 2Completed
- Sponsor
- Grünenthal GmbH
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of axomadol in knee osteoarthritis (OA) (5 arms), sponsored by Grünenthal GmbH. Primary endpoint: Average pain intensity over the preceding 24 hours at final visit. Started Nov 2005; status: completed.
02
Drugs
axomadol
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2005-003360-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003360-26.